Literature DB >> 25715806

The impact of healthcare-associated methicillin-resistant Staphylococcus aureus infections on post-discharge healthcare costs and utilization.

Richard E Nelson1, Makoto Jones1, Chuan-Fen Liu2, Matthew H Samore1, Martin E Evans3, Nicholas Graves4, Bruce Lee5, Michael A Rubin1.   

Abstract

OBJECTIVE: Healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) infections are a major cause of morbidity, mortality, and cost among hospitalized patients. Little is known about their impact on post-discharge resource utilization. The purpose of this study was to estimate post-discharge healthcare costs and utilization attributable to positive MRSA cultures during a hospitalization.
METHODS: Our study cohort consisted of patients with an inpatient admission lasting longer than 48 hours within the US Department of Veterans Affairs (VA) system between October 1, 2007, and November 30, 2010. Of these patients, we identified those with a positive MRSA culture from microbiology reports in the VA electronic medical record. We used propensity score matching and multivariable regression models to assess the impact of positive culture on post-discharge outpatient, inpatient, and pharmacy costs and utilization in the 365 days following discharge.
RESULTS: Our full cohort included 369,743 inpatients, of whom, 3,599 (1.0%) had positive MRSA cultures. Our final analysis sample included 3,592 matched patients with and without positive cultures. We found that, in the 12 months following hospital discharge, having a positive culture resulted in increases in post-discharge pharmacy costs ($776, P<.0001) and inpatient costs ($12,167, P<.0001). Likewise, having a positive culture increased the risk of a readmission (odds ratio [OR]=1.396, P<.0001), the number of prescriptions (incidence rate ratio [IRR], 1.138; P<.0001) and the number of inpatient days (IRR, 1.204; P<.0001,) but decreased the number of subsequent outpatient encounters (IRR, 0.941; P<.008).
CONCLUSIONS: The results of this study indicate that MRSA infections are associated with higher levels of post-discharge healthcare cost and utilization. These findings indicate that financial benefits resulting from infection prevention efforts may extend beyond the initial hospital stay.

Entities:  

Mesh:

Year:  2015        PMID: 25715806     DOI: 10.1017/ice.2015.22

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  10 in total

1.  Economic Analysis of Veterans Affairs Initiative to Prevent Methicillin-Resistant Staphylococcus aureus Infections.

Authors:  Richard E Nelson; Vanessa W Stevens; Karim Khader; Makoto Jones; Matthew H Samore; Martin E Evans; R Douglas Scott; Rachel B Slayton; Marin L Schweizer; Eli L Perencevich; Michael A Rubin
Journal:  Am J Prev Med       Date:  2016-05       Impact factor: 5.043

2.  The Impact of Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Infections on Postdischarge Health Care Costs and Utilization across Multiple Health Care Systems.

Authors:  Richard E Nelson; Makoto Jones; Chuan-Fen Liu; Matthew H Samore; Martin E Evans; Vanessa W Stevens; Thomas Reese; Michael A Rubin
Journal:  Health Serv Res       Date:  2018-10-09       Impact factor: 3.402

Review 3.  Methicillin-Resistant Staphylococcus aureus Control in the 21st Century: Laboratory Involvement Affecting Disease Impact and Economic Benefit from Large Population Studies.

Authors:  Lance R Peterson; Donna M Schora
Journal:  J Clin Microbiol       Date:  2016-06-15       Impact factor: 5.948

4.  Knowledge, attitudes, and practice on the prevention of central line-associated bloodstream infections among nurses in oncological care: A cross-sectional study in an area of southern Italy.

Authors:  Maria Rosaria Esposito; Assunta Guillari; Italo Francesco Angelillo
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

5.  Estimating the burden of antimicrobial resistance: a systematic literature review.

Authors:  Nichola R Naylor; Rifat Atun; Nina Zhu; Kavian Kulasabanathan; Sachin Silva; Anuja Chatterjee; Gwenan M Knight; Julie V Robotham
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-25       Impact factor: 4.887

Review 6.  Streptomyces as a Prominent Resource of Future Anti-MRSA Drugs.

Authors:  Hefa Mangzira Kemung; Loh Teng-Hern Tan; Tahir Mehmood Khan; Kok-Gan Chan; Priyia Pusparajah; Bey-Hing Goh; Learn-Han Lee
Journal:  Front Microbiol       Date:  2018-09-24       Impact factor: 5.640

7.  Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.

Authors:  Xuemei Zhen; Cecilia Stålsby Lundborg; Xueshan Sun; Xiaoqian Hu; Hengjin Dong
Journal:  Antimicrob Resist Infect Control       Date:  2019-08-13       Impact factor: 4.887

8.  Group 1 CD1-restricted T cells contribute to control of systemic Staphylococcus aureus infection.

Authors:  Lavanya Visvabharathy; Samantha Genardi; Liang Cao; Ying He; Francis Alonzo; Evgeny Berdyshev; Chyung-Ru Wang
Journal:  PLoS Pathog       Date:  2020-04-28       Impact factor: 6.823

9.  Mortality, Length of Stay, and Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Elderly Hospitalized Patients in the United States.

Authors:  Richard E Nelson; David Hyun; Amanda Jezek; Matthew H Samore
Journal:  Clin Infect Dis       Date:  2022-03-23       Impact factor: 9.079

10.  Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.

Authors:  Jacqueline T Bork; Emily L Heil; Shanna Berry; Eurides Lopes; Rohini Davé; Bruce L Gilliam; Anthony Amoroso
Journal:  Infect Dis Ther       Date:  2019-05-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.